Streetbeat News

Products Services

AAPL

LPL

Apple Inc. and LG Display Co. Ltd. are reportedly partnering to introduce specialized OLED display materials in future iPad Pro and MacBook models. The partnership aims to produce applications for various industries, with the OLED panels designed to provide the same brightness levels as single-stack counterparts but with reduced power consumption and extended lifespan. This collaboration comes after a decline in iPad sales, attributed to industry-wide softness and missteps.

Portfolio Pulse from Benzinga Neuro

October 24, 2023 | 12:48 pm

PTON

Peloton (NASDAQ:PTON) has officially launched Peloton Row in Canada, expanding its hardware portfolio in the country. The launch follows a survey revealing that 52% of Canadians are interested in using indoor rowing machines for exercise. Peloton Row is available for purchase in Peloton stores across Canada and online. The product offers a low-impact, full-body cardio and strength workout and is available for an introductory offer price of $3,370 CAD until January 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:47 pm

GM

GM's CEO announced that the new Bolt will use LFP batteries, which will result in billions of dollars in capital savings compared to the previous EV plan.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:44 pm

EGRX

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been granted a patent for its pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY®. The patent, which will expire in 2036, has been submitted for listing in the U.S. Food and Drug Administration's Orange Book. This is the second patent to be listed in the Orange Book for PEMFEXY. The company has not received any notice of a Paragraph IV certification for an application referencing PEMFEXY.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:41 pm

INM

LIAN

RTX

Raytheon Technologies reported better-than-expected Q3 results, updated guidance, and announced a $10 billion accelerated share-repurchase program. InMed Pharmaceuticals revealed unique pharmacological effects of INM-901 in Alzheimer's disease in preclinical studies. LianBio entered into an agreement with Bristol Myers Squibb for Mavacamten in China and other Asian markets.

Portfolio Pulse from ryanfaloona@benzinga.com

October 24, 2023 | 12:41 pm

GM

During a conference call, the CEO of General Motors (GM) announced that the company is launching new SUVs with profit margins up to 5 points higher than the models they are replacing.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:40 pm

TBLT

ToughBuilt Industries has launched its StackTech line, a mobile stacking tool storage solution, marking its entry into the Stacking Tool Storage and Toolbox market. The Toolbox category is projected to grow at a CAGR of 8.3% from 2022 to 2032, reaching a market share of USD 6.8 Billion by 2032. The StackTech system has debuted through a leading US home improvement retailer and will expand globally.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:36 pm

MGTX

MeiraGTx Holdings plc (NASDAQ:MGTX), a clinical stage gene therapy company, announced that it will present eight posters and one oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress. The presentations will cover a range of topics including preclinical efficacy of gene therapy for ALS, results of a phase 1 study of gene therapy for radiation-induced xerostomia, and development of alternatives to Triton X-100 cell lysis for AAV2, AAV5 and AAV8 primary recovery.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:35 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) has announced its expansion into the New Zealand market with its Intelligent Fingerprinting Drug Screening System. The system uses fingertip sweat to screen for common drugs of abuse, offering an efficient and non-invasive alternative to traditional drug testing methods. The company's growth strategy includes further expansion throughout Asia Pacific, the United States and Canada.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm

LGVN

Longeveron Inc. (NASDAQ:LGVN) has been featured in a broadcast via NetworkNewsAudio, highlighting the positive top-line results from its Phase 2a trial of Lomecel-B™ for the treatment of mild Alzheimer's disease. The company's CEO, Wa'el Hashad, stated that these results validate the safety and therapeutic potential of Lomecel-B™ and provide a foundation for additional clinical trials. The company is also progressing with its Phase 2 ELPIS II trial in HLHS and Phase 2 program in Aging-related Frailty in Japan.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:33 pm